^
    Back
    Association details:
    Biomarker:AKT1 E17K
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:Truqap (capivasertib) (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

    Published date:
    04/22/2020
    Excerpt:
    A 50% decrease in AKT1 E17K at cycle 2 day 1 was associated with improved PFS. Capivasertib demonstrated clinically meaningful activity in heavily pretreated AKT1 E17K-mutant ER+ MBC patients…
    DOI:
    10.1158/1078-0432.CCR-19-3953